Revelation Biosciences (REVB) Cash from Financing Activities (2020 - 2025)
Revelation Biosciences (REVB) posted quarterly Cash from Financing Activities of -$41166.0 for Q4 2025, down 101.12% year-over-year from $3.7 million in Q4 2024, and down 100.45% quarter-over-quarter from $9.1 million in Q3 2025.
Revelation Biosciences (REVB) Cash from Financing Activities (2020 - 2025) Analysis & Trends
Revelation Biosciences (REVB) has reported Cash from Financing Activities for 6 consecutive years, with -$41166.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Financing Activities fell 101.12% year-over-year to -$41166.0; the TTM figure through Dec 2025 stood at $16.5 million (up 28.53% YoY), while the FY2025 annual figure was $12.5 million, down 2.93% from the prior year.
- Cash from Financing Activities retreated to -$41166.0 in Q4 2025 per REVB's latest filing, from $9.1 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $14.0 million in Q1 2023 and bottomed at -$41166.0 in Q4 2025.
- Historically, Cash from Financing Activities has averaged $5.4 million across 5 years, with a median of $4.5 million in 2022.
- Annual changes were most pronounced in 2021 — Cash from Financing Activities soared 54588.22% — and 2025, when it slumped 101.12%.
- Revelation Biosciences' Cash from Financing Activities stood at $8.0 million in 2021, then slumped by 99.94% to $5000.0 in 2022, then slumped by 99.7% to $15.0 in 2023, then surged by 24586020.0% to $3.7 million in 2024, then plunged by 101.12% to -$41166.0 in 2025.
- Business Quant data shows REVB's Cash from Financing Activities at -$41166.0 in Q4 2025, $9.1 million in Q3 2025, and $3.7 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Revelation Biosciences | 4.17 Mn | -7.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -41,166.00 |
| Dec 31, 2025 | -41,166.00 |
| Sep 30, 2025 | 9.12 Mn |
| Sep 30, 2025 | 9.12 Mn |
| Dec 31, 2024 | 3.69 Mn |
| Dec 31, 2024 | 3.69 Mn |
| Sep 30, 2024 | 3.74 Mn |
| Sep 30, 2024 | 3.74 Mn |
| Mar 31, 2024 | 5.42 Mn |
| Mar 31, 2024 | 5.42 Mn |
| Jun 30, 2023 | 15.00 |
| Jun 30, 2023 | 15.00 |
| Mar 31, 2023 | 14.02 Mn |
| Mar 31, 2023 | 14.02 Mn |
| Dec 31, 2022 | 5,000.00 |
| Dec 31, 2022 | 5,000.00 |
| Sep 30, 2022 | 4.45 Mn |
| Sep 30, 2022 | 4.45 Mn |
| Mar 31, 2022 | 10.74 Mn |
| Mar 31, 2022 | 10.74 Mn |